{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:50Z","timestamp":1792834730001,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to evaluate treatment patterns, adverse events, and drug discontinuations associated with conventional synthetic (csDMARDs), biologic, and targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) and chronic kidney disease (CKD). A retrospective cohort study was conducted on 264 RA patients with CKD, followed between 2015 and 2025. Renal function was assessed using estimated glomerular filtration rate (CKD-epidemiology collaboration) and categorized according to Kidney Disease Improving Global Outcomes guidelines into stages 3 to 5. Demographic data, laboratory parameters, comorbidities, medication history, and all drug-related adverse events were collected. Severe adverse events were defined as those requiring hospitalization, causing drug discontinuation, or resulting in death. Comparisons among CKD stages were performed using chi-square, Fisher exact test, analysis of variance, or Kruskal\u2013Wallis tests as appropriate. Of 264 patients, the median age was 65 years, and 73.9% were female. Hypertension and diabetes were the leading comorbidities and major contributors to CKD etiology. Use of nephrotoxic csDMARDs (methotrexate, leflunomide) and nonsteroidal anti-inflammatory drugs (NSAIDs) decreased with advancing CKD, whereas glucocorticoid use increased. Toxicity from methotrexate, leflunomide, and NSAIDs rose significantly across renal stages (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05 for all). In contrast, adverse event rates for biologic disease-modifying antirheumatic drugs and targeted synthetic disease-modifying antirheumatic drugs did not differ significantly between CKD stages (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05). No renal function-dependent increase in severe adverse events was observed for biologic or targeted therapies. In multivariable analysis, younger age, longer RA disease duration, higher baseline estimated glomerular filtration rate, and higher baseline Disease Activity Score 28-erythrocyte sedimentation rate were independently associated with the occurrence of any adverse event. While csDMARD and NSAID toxicity increase progressively with renal impairment, biologic and targeted synthetic agents maintain a stable safety profile across CKD stages.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050387","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:45Z","timestamp":1787968905000},"page":"e50387","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of renal function on the safety of biologic and synthetic DMARDs in rheumatoid arthritis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-7532","authenticated-orcid":false,"given":"Dilara","family":"Bulut G\u00f6kten","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Atakan","family":"So\u011fur","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoljargal","family":"Sukhbaatar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridvan","family":"Mercan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/joim.13058","article-title":"The importance of differences; on environment and its interactions with genes and immunity in the causation of rheumatoid arthritis.","volume":"287","author":"Klareskog","year":"2020","journal-title":"J Intern Med"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1038\/s41598-025-92150-1","article-title":"Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20\u201354 years from 1990 to 2021.","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5606\/ArchRheumatol.2018.6480","article-title":"Prevalence of rheumatoid arthritis and spondyloarthritis in Turkey: a nationwide study.","volume":"33","author":"Tuncer","year":"2018","journal-title":"Arch Rheumatol"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment.","volume":"27","author":"Bullock","year":"2018","journal-title":"Med Princ Pract"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/gfw315","article-title":"Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients.","volume":"32","author":"Tokoroyama","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10067-007-0625-y","article-title":"Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study.","volume":"26","author":"Karstila","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard-2024-226156","article-title":"Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.","volume":"84","author":"Fukui","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan college of rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis.","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.ajkd.2021.02.338","article-title":"The association of disease activity and estimated GFR in patients with rheumatoid arthritis: findings from the ANSWER study.","volume":"78","author":"Onishi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/ard-2024-225914","article-title":"Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.","volume":"83","author":"Yoshimura","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.reuma.2021.07.001","article-title":"Rheumatoid arthritis and chronic kidney disease under dialysis \u2013 are anti-TNF an option?","volume":"18","author":"Freitas","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"suppl_6","key":"R13-20261024","first-page":"vi5","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria.","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10067-011-1782-6","article-title":"The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.","volume":"30","author":"Senel","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5414\/CNP73431","article-title":"The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients.","volume":"73","author":"Don","year":"2010","journal-title":"Clin Nephrol"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00393-011-0830-6","article-title":"Nierensch\u00e4digung durch methotrexat?","volume":"70","author":"Erdbr\u00fcgger","year":"2011","journal-title":"Z Rheumatol"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/ddc4030036","article-title":"Leflunomide applicability in rheumatoid arthritis: drug delivery challenges and emerging formulation strategies.","volume":"4","author":"Dhiman","year":"2025","journal-title":"Drugs Drug Candidates"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5114\/reum\/177005","article-title":"Rheumatoid arthritis \u2013 medication dosage in chronic kidney disease.","volume":"61","author":"Tyczy\u0144ska","year":"2024","journal-title":"Reumatologia"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/0886022X.2017.1399908","article-title":"Sulfasalazine induces mitochondrial dysfunction and renal injury.","volume":"39","author":"Niknahad","year":"2017","journal-title":"Ren Fail"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00393-014-1480-2","article-title":"Dosage and toxicity of antirheumatic drugs in renal insufficiency.","volume":"74","author":"Weiner","year":"2015","journal-title":"Z Rheumatol"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000544810","article-title":"Disease-modifying antirheumatic drug therapy of inflammatory rheumatic diseases in end-stage kidney disease.","volume":"50","author":"Patschan","year":"2025","journal-title":"Kidney Blood Press Res"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jgh3.13015","article-title":"Upadacitinib in end stage renal disease: a case of acute severe ulcerative colitis.","volume":"7","author":"Hilley","year":"2023","journal-title":"JGH Open"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10238-024-01360-w","article-title":"Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.","volume":"24","author":"Nakayama","year":"2024","journal-title":"Clin Exp Med"},{"key":"R27-20261024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000342333","article-title":"Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases.","volume":"36","author":"Speeckaert","year":"2012","journal-title":"Am J Nephrol"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40620-023-01845-z","article-title":"Tocilizumab (anti-IL-6) treatment for AA renal amyloidosis in a patient with advanced chronic kidney disease, a case report.","volume":"37","author":"Seneschall","year":"2024","journal-title":"J Nephrol"},{"key":"R29-20261024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5414\/CN109971","article-title":"Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: two case reports.","volume":"95","author":"Fukuda","year":"2021","journal-title":"Clin Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:01:09Z","timestamp":1792832469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050387"}},"subtitle":["A retrospective cohort study from a Turkish tertiary center"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":26,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050387","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}